Literature DB >> 23055477

Neurofibromatosis type 1: modeling CNS dysfunction.

David H Gutmann1, Luis F Parada, Alcino J Silva, Nancy Ratner.   

Abstract

Neurofibromatosis type 1 (NF1) is the most common monogenic disorder in which individuals manifest CNS abnormalities. Affected individuals develop glial neoplasms (optic gliomas, malignant astrocytomas) and neuronal dysfunction (learning disabilities, attention deficits). Nf1 genetically engineered mouse models have revealed the molecular and cellular underpinnings of gliomagenesis, attention deficit, and learning problems with relevance to basic neurobiology. Using NF1 as a model system, these studies have revealed critical roles for the NF1 gene in non-neoplastic cells in the tumor microenvironment, the importance of brain region heterogeneity, novel mechanisms of glial growth regulation, the neurochemical bases for attention deficit and learning abnormalities, and new insights into neural stem cell function. Here we review recent studies, presented at a symposium at the 2012 Society for Neuroscience annual meeting, that highlight unexpected cell biology insights into RAS and cAMP pathway effects on neural progenitor signaling, neuronal function, and oligodendrocyte lineage differentiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055477      PMCID: PMC3477849          DOI: 10.1523/JNEUROSCI.3242-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  86 in total

1.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

2.  Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain.

Authors:  D P DiPaolo; R A Zimmerman; L B Rorke; E H Zackai; L T Bilaniuk; A T Yachnis
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

3.  Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons.

Authors:  M Nordlund; X Gu; M T Shipley; N Ratner
Journal:  J Neurosci       Date:  1993-04       Impact factor: 6.167

4.  Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development.

Authors:  D P Huynh; T Nechiporuk; S M Pulst
Journal:  Dev Biol       Date:  1994-02       Impact factor: 3.582

5.  Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro.

Authors:  S J Hewett; D W Choi; D H Gutmann
Journal:  Neuroreport       Date:  1995-07-31       Impact factor: 1.837

6.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

7.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

Authors:  T Jacks; T S Shih; E M Schmitt; R T Bronson; A Bernards; R A Weinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

8.  Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development.

Authors:  M M Daston; N Ratner
Journal:  Dev Dyn       Date:  1992-11       Impact factor: 3.780

9.  Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains.

Authors:  M L Nordlund; T A Rizvi; C I Brannan; N Ratner
Journal:  J Neuropathol Exp Neurol       Date:  1995-07       Impact factor: 3.685

10.  Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons.

Authors:  K S Vogel; C I Brannan; N A Jenkins; N G Copeland; L F Parada
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

View more
  31 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  Apaf1-deficient cortical neurons exhibit defects in axonal outgrowth.

Authors:  Daniela De Zio; Francesca Molinari; Salvatore Rizza; Lucia Gatta; Maria Teresa Ciotti; Anna Maria Salvatore; Søs Grønbæk Mathiassen; Andrzej W Cwetsch; Giuseppe Filomeni; Giuseppe Rosano; Elisabetta Ferraro
Journal:  Cell Mol Life Sci       Date:  2015-05-15       Impact factor: 9.261

3.  Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity.

Authors:  Wissem Deraredj Nadim; Séverine Chaumont-Dubel; Fahima Madouri; Laetitia Cobret; Marie-Ludivine De Tauzia; Pawel Zajdel; Hélène Bénédetti; Philippe Marin; Séverine Morisset-Lopez
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

4.  Neurofibromatosis type 1 alternative splicing is a key regulator of Ras signaling in neurons.

Authors:  Melissa N Hinman; Alok Sharma; Guangbin Luo; Hua Lou
Journal:  Mol Cell Biol       Date:  2014-04-07       Impact factor: 4.272

Review 5.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

Review 6.  Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Authors:  Morgan E Freret; David H Gutmann
Journal:  J Neurosci Res       Date:  2018-04-28       Impact factor: 4.164

7.  Nf1 deletion results in depletion of the Lhx6 transcription factor and a specific loss of parvalbumin+ cortical interneurons.

Authors:  Kartik Angara; Emily Ling-Lin Pai; Stephanie M Bilinovich; April M Stafford; Julie T Nguyen; Katie X Li; Anirban Paul; John L Rubenstein; Daniel Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

8.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

9.  Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.

Authors:  Xiaodong Zhou; Sung-Hoon Kim; Ling Shen; Hyo-Jung Lee; Changyan Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  The mTOR signaling pathway as a treatment target for intracranial neoplasms.

Authors:  Doreen Pachow; Wolfgang Wick; David H Gutmann; Christian Mawrin
Journal:  Neuro Oncol       Date:  2014-08-27       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.